Get started
Windtree Therapeutics, Inc.Windtree Therapeutics, Inc.Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

WINT chart


Full chart

WINT upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.42 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−157.86 USD
Net income (FY)
‪−1.79 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪748.36 K‬
Beta (1Y)
1.97

Employees


Employees (FY)
14
Change (1Y)
−1 −6.67%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−127.64 K‬ USD

About Windtree Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Jed Andrew Latkin
Website
windtreetx.com
Headquarters
Warrington
Founded
1992
FIGI
BBG000JMNPX3
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. It's portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

WINT news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as WINT.

Frequently Asked Questions


The current price of WINT is 1.14 USD — it has decreased by −5.79% in the past 24 hours. Watch Windtree Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Windtree Therapeutics, Inc. stocks are traded under the ticker WINT.
WINT stock has risen by 2.70% compared to the previous week, the month change is a −32.94% fall, over the last year Windtree Therapeutics, Inc. has showed a −99.55% decrease.
We've gathered analysts' opinions on Windtree Therapeutics, Inc. future price: according to them, WINT price has a max estimate of 4.00 USD and a min estimate of 4.00 USD. Watch WINT chart and read a more detailed Windtree Therapeutics, Inc. stock forecast: see what analysts think of Windtree Therapeutics, Inc. and suggest that you do with its stocks.
WINT reached its all-time high on Mar 1, 1996 with the price of 8,930,250,000.00 USD, and its all-time low was 1.01 USD and was reached on Apr 23, 2025. View more price dynamics on WINT chart.
See other stocks reaching their highest and lowest prices.
WINT stock is 10.36% volatile and has beta coefficient of 1.97. Track Windtree Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Windtree Therapeutics, Inc. there?
Today Windtree Therapeutics, Inc. has the market capitalization of ‪854.25 K‬, it has increased by 335.42% over the last week.
Yes, you can track Windtree Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Windtree Therapeutics, Inc. is going to release the next earnings report on May 14, 2025. Keep track of upcoming events with our Earnings Calendar.
WINT earnings for the last quarter are −32.00 USD per share, whereas the estimation was −39.00 USD resulting in a 17.95% surprise. The estimated earnings for the next quarter are −180.00 USD per share. See more details about Windtree Therapeutics, Inc. earnings.
Windtree Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 0.00 USD. In the next quarter, revenue is expected to reach ‪2.20 M‬ USD.
WINT net income for the last quarter is ‪2.77 M‬ USD, while the quarter before that showed ‪−2.75 M‬ USD of net income which accounts for 200.65% change. Track more Windtree Therapeutics, Inc. financial stats to get the full picture.
No, WINT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 29, 2025, the company has 14 employees. See our rating of the largest employees — is Windtree Therapeutics, Inc. on this list?
Like other stocks, WINT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Windtree Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Windtree Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Windtree Therapeutics, Inc. stock shows the sell signal. See more of Windtree Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.